137506-14-0

Basic information

• Product Name: 5-METHYL-4-PHENYL-2(3H)-THIAZOLONE HYDRAZONE
• Synonyms: 5-METHYL-4-PHENYL-2(3H)-THIAZOLONE HYDRAZONE
• CAS NO: 137506-14-0
• Molecular Formula: C10H11N3S
• Molecular Weight: 205.28
• Mol File: 137506-14-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-METHYL-4-PHENYL-2(3H)-THIAZOLONE HYDRAZONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-4-PHENYL-2(3H)-THIAZOLONE HYDRAZONE(137506-14-0)
• EPA Substance Registry System: 5-METHYL-4-PHENYL-2(3H)-THIAZOLONE HYDRAZONE(137506-14-0)

Safety Data

• Hazardous Substances Data: 137506-14-0(Hazardous Substances Data)

Upstream product

• 23022-83-5 1-bromo-1-phenyl-2-propanone 
• 4426-72-6 hydrazine carboxamide 
• 2114-00-3 2-bromo-1-phenyl-1-propanone 
• 93-55-0 1-phenyl-propan-1-one 
• 79-19-6 thiosemicarbazide 

Downstream Products

• 1429312-22-0 6-methyl-5-phenylthiazolo[2,3-c][1,2,4]triazole-3-thiol 

Relevant articles and documents

Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents

It has been proven that inhibiting human dihydroorotate dehydrogenase (hDHODH) restricts the growth of rapidly proliferating cells, thus hDHODH can be developed as a promising target for the treatment of immunological disease and cancer. Here, a succession of substituted hydrazino-thiazole derivatives were designed, synthesized, and biologically evaluated through structure-based optimization, of which compound 22 was the most potent inhibitor of hDHODH with an IC50 value of 1.8 nM. Furthermore, 22 exhibited much better antiproliferative activity than brequinar, both in HCT-116 and BxPC-3 cancer cell lines. Flow cytometry analysis revealed that 22 induced S phase cell cycle arrest and promoted induction of apoptosis. All results established a proof that blocking the pyrimidine de novo synthesis pathway by inhibiting the rate-limiting enzyme hDHODH is an attractive therapy for cancer.

ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES

This disclosure relates to compounds, compositions and methods for the treatment of various disorders. In particular, the disclosure relates to thiazolotriazole and thiazoloimidazole compounds which agonize the activity of the protein TGR5. Formula (I)

REGULATION OF PROTEIN SYNTHESIS

A composition and method for inhibiting proliferation of a tumor cell compared to a non-tumor cell. Also described are methods of screening for a composition that inhibits cap-dependent translation compared to cap-independent translation of proteins